Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 10/20 | 0.51 |
| ▸ | RAMP1 | O60894 | 9/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 4/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30683670 | 1.00 | CALCRL (0.51) | CALCRLRAMP1HDAC4HDAC3HDAC1 | |
| SCHEMBL3706203 | 0.89 | RAMP1 (0.43) | CALCRLRAMP1HDAC4SIGMAR1KDM1A | |
| SCHEMBL3698148 | 0.88 | RAMP1 (0.45) | CALCRLRAMP1CCKBR | |
| SCHEMBL15227809 | 0.88 | RAMP1 (0.45) | CALCRLRAMP1CCKBR | |
| SCHEMBL26619367 | 0.88 | RAMP1 (0.45) | CALCRLRAMP1CCKBR | |
| SCHEMBL16653123 | 0.88 | CALCRL (0.53) | CALCRLRAMP1CCKBR | |
| SCHEMBL3699627 | 0.88 | CALCRL (0.53) | CALCRLRAMP1CCKBR | |
| SCHEMBL20664219 | 0.87 | RAMP1 (0.48) | CALCRLRAMP1HDAC4HDAC3HDAC1 | |
| SCHEMBL20664272 | 0.87 | RAMP1 (0.48) | CALCRLRAMP1HDAC4HDAC3HDAC1 | |
| SCHEMBL15280640 | 0.87 | RAMP1 (0.48) | CALCRLRAMP1HDAC4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2849568-B1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3430906-A1 | CRYSTALLINE FORMS OF CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-01-23 | — | — | EP | disclosed |
| US-9487523-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9174989-B2 | Process for making CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112067-A1 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | CCKBR, BDKRB2, CALCR | CALCRL 7/4885RAMP1 19/4885HDAC4 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.